Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer
Received 8 February 2010; accepted 27 April 2010. published online 31 May 2010.
Abstract
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence ‘Tumeurs Réfractaires de la Thyroïde’, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France
Author for correspondence: M. Schlumberger, Institut Gustave Roussy, 94800 Villejuif, France. Tel: +33-142116095; Fax: +33-142116363.
ABSTRACT